TNF Inhibitors - Global Market Trajectory & Analytics

Global TNF Inhibitors Market to Reach $45.5 Billion by 2027

Amid the COVID-19 crisis, the global market for TNF Inhibitors estimated at US$41.6 Billion in the year 2020, is projected to reach a revised size of US$45.5 Billion by 2027, growing at a CAGR of 1.3% over the period 2020-2027.



The U.S. Market is Estimated at $11.3 Billion, While China is Forecast to Grow at 2.7% CAGR

The TNF Inhibitors market in the U.S. is estimated at US$11.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.5 Billion by the year 2027 trailing a CAGR of 2.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0% and 0.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.4% CAGR.

Select Competitors (Total 41 Featured):

• AbbVie Inc.
• Amgen Inc.
• Biocad Biopharmaceutical Co.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• EPIRUS Biopharmaceuticals, Inc.
• Innovent Biologics, Inc.
• Janssen Biotech, Inc.
• Johnson & Johnson Services, Inc.
• Merck & co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Shanghai Henlius Biotech, Inc.
• UCB S.A.